ReNeuron Group Quote more <\/p>\n
Price: 3.62 <\/p>\n
Chg: -0.19 <\/p>\n
Chg %: -4.87% <\/p>\n
Date: 16:38 <\/p>\n
Stem cell therapy group Reneuron said it remains on track with the first patients having been dosed in two its clinical trials. <\/p>\n
The phase II trial for the ReN001 cell therapy candidate for stroke disability and the phase I trail for ReN009 cell therapy candidate for critical limb ischaemia have both begun. <\/p>\n
The ReN001 trial is on course to have generated six month follow-up data by the end of 2015, while ReN009 study should give results in the first half of next year. <\/p>\n
Chief executive officer (CEO) Michael Hunt said that Reneuron's core therapeutic programmes remain on track towards \"further important clinical milestones\" over the next 18 months. <\/p>\n
\"In particular, the commencement of dosing of patients in two new clinical trials, in stroke and limb ischaemia, marks another significant step in Reneuron's evolution into a fully-fledged clinical development business and a leading player in the increasingly exciting field of cell therapy and regenerative medicine,\" Hunt said. <\/p>\n
<\/p>\n
Read more here: <\/p>\n
Reneuron on track for clinical milestones as studies get underway<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" ReNeuron Group Quote more Price: 3.62 Chg: -0.19 Chg %: -4.87% Date: 16:38 Stem cell therapy group Reneuron said it remains on track with the first patients having been dosed in two its clinical trials. Continue reading